ALP opens OMEGA 1 Bangna smart warehouse spanning 260,000 sq m with Zero CAPEX model

Ocado Group's fair value estimate has been lifted to about £2.45 from about £2.35, with published analyst price targets now ranging between 245 GBp and 330 GBp. Berenberg recently initiated coverage of Ocado Group with a Buy rating and a 330 GBp price target, citing the company's software and robotics offering for online grocery fulfilment and two customer wins in 2026 as key drivers. JPMorgan kept its Overweight stance on Ocado Group but cut its price target to 245 GBp from 290 GBp, a move that points to lingering questions over execution, contract timing and capital needs. The gap between the two targets underlines how sensitive Ocado Group's valuation is to differing views on contract flow and the pace at which its technology converts into cash flows. Behind the revised fair value, revenue growth assumptions still point to a decline, easing from about 1.82% to about 1.31%, while profit margin expectations edged down from about 1.99% to about 1.96%, the future P/E shifted from about 77.0x to about 79.9x, and the discount rate moved from about 8.95% to about 8.80%.

Becton, Dickinson and Company has deployed its next-generation pharmacy automation robot, BD Vmax 160, at Fairview Health Services, marking the first U.S. health system to adopt the system. Fairview, which fills an average of 20,000 prescriptions per week across 25 outpatient pharmacies and mail-order services in Minnesota, is building on an existing collaboration with BD that includes the BD Parata Max 2 high-speed vial filling robot and the BD Incada Connected Care Platform. The Vmax 160 is designed for centralized fulfillment environments, featuring the BD EasyLoad system for overnight inventory replenishment with a reported three-second loading time per tote and 99.8% accuracy, automated labeling that supports requirements across all 50 states, cold-chain support for medications stored between 2°C and 8°C, and smart expiry detection that blocks expired products from being dispensed. Following the announcement, BDX stock gained 2.8% at yesterday's close, though shares have lost 5.8% year to date against the industry's 5% growth, with the S&P 500 up 11.1% over the same period. BDX currently has a market capitalization of $49 billion. Separately, BD said the STANCE trial of GalaFLEX LITE Scaffold surpassed 50% of its maximum planned enrollment with 274 patients treated across 33 U.S. sites, and it completed enrollment of 477 patients across 32 U.S. and European sites in the PREVENT trial evaluating Phasix Mesh for incisional hernia prevention.